argenx Past Earnings Performance
Past criteria checks 0/6
argenx's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 55.2% per year.
Key information
-8.0%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs Industry Growth | -3.6% |
| Revenue growth rate | 55.2% |
| Return on equity | -4.8% |
| Net Margin | -12.3% |
| Next Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Is argenx SE (EBR:ARGX) Trading At A 45% Discount?
Aug 24
Results: argenx SE Confounded Analyst Expectations With A Surprise Profit
Jul 29argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up
Jun 26argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet
May 01Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects
Apr 11Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report
Mar 24Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report
Mar 05argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate
Feb 23Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely
Dec 18Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher
Jul 28An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued
Jul 17Revenues Tell The Story For argenx SE (EBR:ARGX)
Jun 20argenx (EBR:ARGX) Is Using Debt Safely
May 08We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth
Apr 20Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?
Dec 27Revenue & Expenses Breakdown
How argenx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,660 | -204 | 892 | 0 |
| 31 Mar 24 | 1,451 | -328 | 799 | 0 |
| 31 Dec 23 | 1,269 | -295 | 712 | 0 |
| 30 Sep 23 | 1,029 | -234 | 638 | 0 |
| 30 Jun 23 | 835 | -397 | 555 | 0 |
| 31 Mar 23 | 639 | -511 | 520 | 0 |
| 31 Dec 22 | 441 | -710 | 472 | 0 |
| 30 Sep 22 | 286 | -909 | 434 | 0 |
| 30 Jun 22 | 146 | -907 | 407 | 0 |
| 31 Mar 22 | 381 | -595 | 352 | 0 |
| 31 Dec 21 | 528 | -408 | 308 | 0 |
| 30 Sep 21 | 510 | -373 | 270 | 0 |
| 30 Jun 21 | 526 | -319 | 233 | 0 |
| 31 Mar 21 | 206 | -573 | 204 | 0 |
| 31 Dec 20 | 62 | -608 | 172 | 0 |
| 30 Sep 20 | 75 | -535 | 144 | 0 |
| 30 Jun 20 | 70 | -359 | 110 | 0 |
| 31 Mar 20 | 73 | -275 | 86 | 0 |
| 31 Dec 19 | 93 | -181 | 72 | 0 |
| 30 Sep 19 | 72 | -109 | 56 | 0 |
| 30 Jun 19 | 68 | -104 | 49 | 0 |
| 31 Mar 19 | 70 | -47 | 37 | 0 |
| 31 Dec 18 | 33 | -76 | 31 | 0 |
| 30 Sep 18 | 41 | -56 | 27 | 0 |
| 30 Jun 18 | 44 | -47 | 22 | 0 |
| 31 Mar 18 | 50 | -46 | 18 | 0 |
| 31 Dec 17 | 49 | -34 | 15 | 0 |
| 30 Sep 17 | 42 | -30 | 11 | 0 |
| 30 Jun 17 | 39 | -25 | 10 | 0 |
| 31 Mar 17 | 23 | -29 | 10 | 0 |
| 31 Dec 16 | 18 | -22 | 7 | 0 |
| 30 Sep 16 | 17 | -20 | 7 | 0 |
| 30 Jun 16 | 14 | -17 | 6 | 0 |
| 31 Mar 16 | 12 | -17 | 6 | 0 |
| 31 Dec 15 | 11 | -17 | 5 | 0 |
| 30 Sep 15 | 10 | -16 | 5 | 0 |
| 30 Jun 15 | 9 | -14 | 5 | 0 |
| 31 Mar 15 | 7 | -12 | 4 | 0 |
| 31 Dec 14 | 7 | -12 | 4 | 0 |
| 30 Sep 14 | 6 | -10 | 4 | 0 |
| 30 Jun 14 | 7 | -8 | 3 | 0 |
| 31 Mar 14 | 7 | -9 | 3 | 0 |
| 31 Dec 13 | 7 | -8 | 3 | 0 |
Quality Earnings: ARGX is currently unprofitable.
Growing Profit Margin: ARGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARGX is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare ARGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.8%).
Return on Equity
High ROE: ARGX has a negative Return on Equity (-4.79%), as it is currently unprofitable.